产品说明书

TAK1/MAP4K2 inhibitor 1

Print
Chemical Structure| 1315330-11-0 同义名 : -
CAS号 : 1315330-11-0
货号 : A756511
分子式 : C29H31F3N6O2
纯度 : 98+%
分子量 : 552.591
MDL号 : MFCD22572824
存储条件：

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(90.48 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 B-Raf inhibitor, a pyrazine and pyrrolo[2,3-b]pyridine derivative, is useful in the treatment of cancer and proliferative diseases.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03181100 Malignant Neoplasms of Thyroid... 展开 >> and Other Endocrine Glands Anaplastic Thyroid Carcinoma Poorly Differentiated Thyroid Cancer 收起 << Phase 2 Recruiting July 2023 United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Clinical Research Operations       mcabani@mdanderson.org    Contact       mcabani@mdanderson.org 收起 <<
NCT01978236 Melanoma and Brain Metastases Phase 2 Terminated(This study was term... 展开 >>inated due to the limited enrollment.) 收起 << - United States, Pennsylvania ... 展开 >> GSK Investigational Site Pittsburgh, Pennsylvania, United States, 15232 United States, Texas GSK Investigational Site Houston, Texas, United States, 77030 Australia, New South Wales GSK Investigational Site North Sydney, New South Wales, Australia, 2060 收起 <<
NCT01738451 Cancer Phase 1 Completed - United States, Arizona ... 展开 >> GSK Investigational Site Scottsdale, Arizona, United States, 85259 United States, Tennessee GSK Investigational Site Memphis, Tennessee, United States, 38120 GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site San Antonio, Texas, United States, 78229 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84112-5550 Australia, Victoria GSK Investigational Site Heidelberg, Victoria, Australia, 3084 GSK Investigational Site Melbourne, Victoria, Australia, 3004 United Kingdom GSK Investigational Site London, United Kingdom, W1G 6AD 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.81mL

0.36mL

0.18mL

9.05mL

1.81mL

0.90mL

18.10mL

3.62mL

1.81mL
参考文献

[1]Herr R, Kohler M, et al. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer Res. 2015 Jan 1;75(1):216-29.

[2]Arora R, Di Michele M, et al. Structural investigation of B-Raf paradox breaker and inducer inhibitors. J Med Chem. 2015 Feb 26;58(4):1818-31.